2. Search Result
Search Result
Results for "

TXNIP

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

2

Natural
Products

1

Recombinant Proteins

2

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-115688
    TXNIP-IN-1
    1 Publications Verification

    		 Arrestin Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    TXNIP-IN-1 is TXNIP-TRX (thioredoxin-interacting protein- thioredoxin) complex inhibitor extracted from patent US20200085800A1, Compound 1. TXNIP-IN-1 can be used in the research of TXNIP-TRX complex associated metabolic disorder (diabetes), cardiovascular disease, or inflammatory disease .
    TXNIP-IN-1
  • HY-115688A
    (S)-TXNIP-IN-1
    1 Publications Verification

    		 Others Cardiovascular Disease Others
    (S)-TXNIP-IN-1 is the less active S-enantiomer of TXNIP-IN-1 (HY-115688). TXNIP-IN-1 is a TXNIP-TRX complex inhibitor which can be used in the research of TXNIP-TRX complex associated metabolic disorder (diabetes), cardiovascular disease, or inflammatory disease
    (S)-TXNIP-IN-1
  • HY-141623
    SRI-37330 hydrochloride
    2 Publications Verification

    		 Arrestin Metabolic Disease
    SRI-37330 hydrochloride is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. SRI-37330 hydrochloride inhibits glucagon secretion and function, reduces hepatic glucose production and reverses hepatic steatosis. SRI-37330 hydrochloride can be used for type 2 diabetes research .
    SRI-37330 hydrochloride
  • HY-142114
    SRI-37330
    2 Publications Verification

    		 Others Metabolic Disease
    SRI-37330 is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. SRI-37330 inhibits glucagon secretion and function, reduces hepatic glucose production and reverses hepatic steatosis. SRI-37330 can be used for type 2 diabetes research .
    SRI-37330
  • HY-B0004
    Doxofylline

    		Adenosine Receptor Phosphodiesterase (PDE) Reactive Oxygen Species Inflammation/Immunology
    Doxofylline is an orally active PDE IV inhibitor and A1AR antagonist. Doxofylline reduces inflammation in epithelial cells via inhibiting mitochondrial ROS production and amelioration of multiple cellular pathways (NLRP3-TXNIP inflammasome activation). Doxophylline can be used in studies of asthma, chronic obstructive pulmonary disease, and bronchospasm .
    Doxofylline
  • HY-N0496
    Ruscogenin
    3 Publications Verification

    		 NOD-like Receptor (NLR) Cardiovascular Disease
    Ruscogenin, an important steroid sapogenin derived from Ophiopogon japonicus, attenuates cerebral ischemia-induced blood-brain barrier dysfunction by suppressing TXNIP/NLRP3 inflammasome activation and the MAPK pathway. Ruscogenin exerts significant anti-inflammatory and anti-thrombotic activities. Ruscogenin has orally bioactivity .
    Ruscogenin
  • HY-RS15295
    TXNIP Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    TXNIP Human Pre-designed siRNA Set A contains three designed siRNAs for TXNIP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TXNIP Human Pre-designed siRNA Set A
    TXNIP Human Pre-designed siRNA Set A
  • HY-155248
    HL23

    		HDAC Cancer
    HL23 is a histone deacetylase (HDAC) inhibitor with activity against hepatocellular carcinoma (HCC). HL23 enhances acetylation of the TXNIP promoter and upregulates TXNIP expression, thereby mediating potassium channel activity and triggering TXNIP-dependent potassium deprivation. HL23 inhibits HCC progression and metastasis and has a synergistic effect with Sorafenib (HY-10201) and is more potent than Sorafenib+Vorinostat (HY-10221) .
    HL23
  • HY-B0004R
    Doxofylline (Standard)

    		Adenosine Receptor Phosphodiesterase (PDE) Reactive Oxygen Species Inflammation/Immunology
    Doxofylline (Standard) is the analytical standard of Doxofylline. This product is intended for research and analytical applications. Doxofylline is an orally active PDE IV inhibitor and A1AR antagonist. Doxofylline reduces inflammation in epithelial cells via inhibiting mitochondrial ROS production and amelioration of multiple cellular pathways (NLRP3-TXNIP inflammasome activation). Doxophylline can be used in studies of asthma, chronic obstructive pulmonary disease, and bronchospasm .
    Doxofylline (Standard)
  • HY-169298
    Ferroptosis-IN-15

    		Ferroptosis Cancer
    Ferroptosis-IN-15 (compound 12) is a potent inhibitor of ferroptosis, with the EC50s of 0.76 and 0.67 μM in A375 cells and 786-O cells, respectively.Ferroptosis-IN-15 is a potential iron chelator and radical trapping antioxidant .
    Ferroptosis-IN-15
  • HY-149216
    Anticancer agent 103

    		Others Cancer
    Anticancer agent 103 (Compound 2k) is a potent anticancer agent .
    Anticancer agent 103
  • HY-124418
    SBI-477
    1 Publications Verification

    		 Fluorescent Dye Metabolic Disease
    SBI-477 is a chemical probe stimulated insulin signaling by deactivating the transcription factor MondoA, leading to reduced expression of the insulin pathway suppressors thioredoxin-interacting protein (TXNIP) and arrestin domain–containing 4 (ARRDC4). SBI-477 coordinately inhibits triacylglyceride (TAG) synthesis and enhances basal glucose uptake in human skeletal myocytes .
    SBI-477
  • HY-N0496R
    Ruscogenin (Standard)

    		NOD-like Receptor (NLR) Cardiovascular Disease
    Ruscogenin (Standard) is the analytical standard of Ruscogenin. This product is intended for research and analytical applications. Ruscogenin, an important steroid sapogenin derived from Ophiopogon japonicus, attenuates cerebral ischemia-induced blood-brain barrier dysfunction by suppressing TXNIP/NLRP3 inflammasome activation and the MAPK pathway. Ruscogenin exerts significant anti-inflammatory and anti-thrombotic activities. Ruscogenin has orally bioactivity .
    Ruscogenin (Standard)
  • HY-122682
    SBI-993

    		Drug Derivative Metabolic Disease
    SBI-993 is a SBI-477 analog with improved potency and suitable pharmacokinetic properties for in vivo bioavailability. SBI-993 stimulates insulin signaling by deactivating the transcription factor MondoA .
    SBI-993
  • HY-19330
    DASA-58
    Maximum Cited Publications
    13 Publications Verification

    		 Pyruvate Kinase Metabolic Disease Cancer
    DASA-58 is a potential pyruvate kinase isozyme (PKM2) allosteric activator. DASA-58 can be used for the research of metabolism and kinds of cancer .
    DASA-58

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: